Lucid DiagnosticsLUCD +1.90%20 Debt-to-EBITDA is -0.49 as of Mar. 2026. GuruFocus rates LUCD with a GF Score™ of 20/100 and a GF Value™ of $0.82 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 468 Medical Devices & Instruments companies, Lucid Diagnostics ranks worse than 213675% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Lucid Diagnostics's Debt-to-EBITDA or its related term are showing as below:
LUCD'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.61 Med: -0.38 Max: -0.04
Current: -0.61
During the past 7 years, the highest Debt-to-EBITDA Ratio of Lucid Diagnostics was -0.04. The lowest was -0.61. And the median was -0.38.
LUCD's Debt-to-EBITDA is ranked worse than 100% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 1.555
vs LUCD: -0.61
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Lucid Diagnostics Debt-to-EBITDA Related Terms
Lucid Diagnostics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Lucid Diagnostics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LUCD vs QTRX, INFU, APYX: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Lucid Diagnostics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lucid Diagnostics Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lucid Diagnostics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Lucid Diagnostics (LUCD) has a Debt-to-EBITDA of -0.49 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Lucid Diagnostics. According to the industry distribution chart, Lucid Diagnostics ranks #999999 out of 468 companies in the Medical Devices & Instruments industry.
Is Lucid Diagnostics' Debt-to-EBITDA too high?
Lucid Diagnostics' current Debt-to-EBITDA is -0.49. Based on the distribution chart, Lucid Diagnostics ranks #999999 out of 468 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Lucid Diagnostics has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' Debt-to-EBITDA compare to QTRX and INFU?
According to the Medical Devices & Instruments industry distribution chart, Lucid Diagnostics ranks #999999 out of 468 companies for Debt-to-EBITDA. This places Lucid Diagnostics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.56, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Lucid Diagnostics. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lucid Diagnostics's current Debt-to-EBITDA is -0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.82, compared to a current price of $1.08 — trading 31.7% above its estimated fair value. The current Debt-to-EBITDA is -0.49. Lucid Diagnostics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current Debt-to-EBITDA is -0.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lucid Diagnostics (LUCD) Overvalued in 2026?
Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued.
The current stock price of $1.08 is trading 31.7% above its estimated GF Value™ of $0.82.
GuruFocus considers Lucid Diagnostics to be Significantly Overvalued.
Key valuation signals for LUCD:
Debt-to-EBITDA: -0.49
GF Value™: $0.82 vs. price of $1.08 (31.7% above fair value)
No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
20GF Score
Get the complete analysis for LUCD
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUCD has been successfully added to your 
